{"id":961396,"date":"2026-05-12T08:52:57","date_gmt":"2026-05-12T12:52:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/"},"modified":"2026-05-12T08:52:57","modified_gmt":"2026-05-12T12:52:57","slug":"ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/","title":{"rendered":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKVILLE, Md. and SUZHOU, China, May  12, 2026  (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201c<strong>Ascentage Pharma<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d),\u00a0a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company\u2019s management is scheduled to participate in three upcoming investor conferences.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;text-align:justify\">B. Riley Commercial\/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18<sup>th<\/sup><\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19<sup>th<\/sup><\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">Jefferies Global Healthcare Conference in New York: One-on-one meetings and presentation at 8:10 am EDT on June 3<sup>rd<\/sup>\n<\/li>\n<\/ul>\n<p align=\"justify\">The webcasts for the fireside chat and presentation can be accessed by visiting the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xXW6RVIXBNVKxvZx88D3C_3ip252OJi7Q7x2_3iLQV5_0SAxirCPAbPhn3qlM-IZSrFwze_0DCsLlExef2brqH18hrc9G_LWtBPbxbxsuAo=\" rel=\"nofollow\" target=\"_blank\">Events<\/a> page in the Investor Relations section of Ascentage Pharma\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About Ascentage Pharma Group International<\/strong>\n      <\/p>\n<p align=\"justify\">Ascentage Pharma Group International\u00a0(NASDAQ: AAPG; HKEX: 6855) (<strong>\u201cAscentage Pharma\u201d<\/strong>\u00a0or the\u00a0<strong>\u201cCompany\u201d<\/strong>) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.<\/p>\n<p align=\"justify\">The Company\u2019s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in\u00a0China\u00a0for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first- and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL).\u00a0Ascentage Pharma\u00a0is currently conducting an FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.<\/p>\n<p align=\"justify\">The Company\u2019s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China\u2019s\u00a0National Medical Products Administration\u00a0(NMPA) for the treatment of adult patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who have previously received at least one systemic therapy including Bruton\u2019s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL\/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL\/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.<\/p>\n<p align=\"justify\">Leveraging its robust R&amp;D capabilities,\u00a0Ascentage Pharma\u00a0has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as\u00a0Dana-Farber Cancer Institute,\u00a0Mayo Clinic,\u00a0National Cancer Institute\u00a0and the\u00a0University of Michigan. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j6v9NH8GkkGSnqUpLGBeKQ7JGjfFtGVxuUsRyh-ZxhgO8ttrhRs9G5VP7V8xPD24yTN3pdUTihD-nkgz6CtO3VWoR8pQSkKiGTJGWZLuQ_AYTDyjzm79hJ2t1tG9k7BuAYeymK_G2OAx4wufi0bmDY4zfTU4-ffC-Iw2gpNJEolsGRIS0XMNkKLzTnGvvIu8vzjv-YxdHaxYWGP7ZPE1TsEIiBdoY75Vg8FEMVhIStIu6MVoyWQDklA_P3HpW0cVRgRcrgQyuJCmsGZTjqB2Dg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ascentage.com\/<\/a><\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma\u2019s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma\u2019s filings with the SEC, including those set forth in the sections titled \u201cRisk factors\u201d and \u201cCautionary note regarding forward-looking statements\u201d in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed \u201cForward-looking Statements\u201d and \u201cRisks Factors\u201d in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and\/or The Stock Exchange of Hong Kong Limited, where the Company\u2019s ordinary shares are listed, it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company\u2019s management.<\/p>\n<p align=\"justify\">As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma\u2019s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements.\u00a0Ascentage Pharma\u00a0does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Stella Yang<br \/>Ascentage Pharma<br \/>Stella.Yang@ascentage.com<br \/>+1 (301) 792-6286<\/p>\n<p>Stephanie Carrington<br \/>ICR Healthcare<br \/>AscentageIR@icrhealthcare.com<br \/>+1 (646) 277-1282<\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Sean Leous<br \/>ICR Healthcare<br \/>AscentagePR@icrhealthcare.com<br \/>+1 (646) 866-4012<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjAxYzQxZjMtYjkzYS00NDliLTlhZmEtYzk2NjQ2ZDAzZTliLTEzMDcyMzEtMjAyNi0wNS0xMi1lbg==\/tiny\/ASCENTAGE-PHARMA-GROUP-INTERNA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d),\u00a0a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company\u2019s management is scheduled to participate in three upcoming investor conferences. B. Riley Commercial\/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18th Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19th Jefferies Global Healthcare Conference in New York: One-on-one meetings and presentation at 8:10 am EDT on June 3rd The webcasts for the fireside chat and presentation can &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascentage Pharma to Participate in Three Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961396","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d),\u00a0a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company\u2019s management is scheduled to participate in three upcoming investor conferences. B. Riley Commercial\/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18th Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19th Jefferies Global Healthcare Conference in New York: One-on-one meetings and presentation at 8:10 am EDT on June 3rd The webcasts for the fireside chat and presentation can &hellip; Continue reading &quot;Ascentage Pharma to Participate in Three Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T12:52:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascentage Pharma to Participate in Three Upcoming Investor Conferences\",\"datePublished\":\"2026-05-12T12:52:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/\"},\"wordCount\":879,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/\",\"name\":\"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\",\"datePublished\":\"2026-05-12T12:52:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma to Participate in Three Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","og_description":"ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d),\u00a0a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company\u2019s management is scheduled to participate in three upcoming investor conferences. B. Riley Commercial\/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18th Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19th Jefferies Global Healthcare Conference in New York: One-on-one meetings and presentation at 8:10 am EDT on June 3rd The webcasts for the fireside chat and presentation can &hellip; Continue reading \"Ascentage Pharma to Participate in Three Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T12:52:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","datePublished":"2026-05-12T12:52:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/"},"wordCount":879,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/","name":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=","datePublished":"2026-05-12T12:52:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc0MiM3NTk2MjUzIzIyOTU2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961396"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961396\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}